R&D channel feed

FDA's pain ad­comm de­bates clin­i­cal tri­al de­signs for opi­oid post-mar­ket­ing tri­als

3 years ago
Pharma
FDA+

Karyopharm stock drops af­ter in­hibitor's PhI da­ta show low­er dose not as ef­fec­tive: #AACR23

3 years ago

In a leaked ab­stract, J&J's cell ther­a­py ap­pears to have dra­mat­ic ben­e­fits for mul­ti­ple myelo­ma pa­tients

3 years ago
Pharma
Cell/Gene Tx

KRAS, one of can­cer’s tough­est tar­gets, sees a surge of new ther­a­pies try­ing to lim­it side ef­fects: #AACR23

3 years ago

Palleon un­veils PhI look at 'lawn mow­er' ap­proach to gly­coim­munol­o­gy: #AACR23

3 years ago
People

Basilea push­es back FDA sub­mis­sion for an­tibi­ot­ic over CMO is­sues

3 years ago
Manufacturing

So­cial me­dia is fu­el­ing en­thu­si­asm for new weight loss drugs. Are reg­u­la­tors watch­ing?

3 years ago
Marketing

#trek­for­to­mor­row: Ear­ly lessons from the trail

3 years ago
People
Biotech Voices

PhRMA calls doc­u­ment de­struc­tion part of new guid­ance on drug price ne­go­ti­a­tions 'un­con­sti­tu­tion­al'

3 years ago
Law

Kin­nate Bio­phar­ma touts ear­ly ef­fi­ca­cy in pan-RAF pro­gram: #AACR23

3 years ago

Vax­cyte un­veils new da­ta on chal­lenger to Pfiz­er’s Pre­vnar, heads to­ward PhI­II

3 years ago

Re­gen­eron re­veals da­ta be­hind de­pri­or­i­tized BC­MA/CD3 bis­pe­cif­ic: #AACR23

3 years ago

GSK stopped two UTI an­tibi­ot­ic tri­als ear­ly af­ter meet­ing ef­fi­ca­cy end­points. Now it’s shar­ing the full da­ta

3 years ago

Roche's com­bo ther­a­py re­duces risk of liv­er can­cer re­turn­ing but rais­es safe­ty ques­tions: #AACR23

3 years ago

As­traZeneca lines up com­pe­ti­tion with Mer­ck in lung can­cer be­fore and af­ter surgery: #AACR23

3 years ago

Mer­ck­'s Keytru­da-chemo re­duces risk of death from bil­iary tract can­cer by 17%: #AACR23

3 years ago

Mod­er­na and Mer­ck pre­pare for PhI­II tri­al of can­cer vac­cine, and an ex­pan­sion to lung can­cer: #AACR23

3 years ago
Pharma

MindMed gains af­ter in­ves­ti­ga­tor tri­al of LSD shows im­pact on ma­jor de­pres­sion

3 years ago

Swedish biotech Guard Ther­a­peu­tics to stop PhII af­ter in­ter­im re­view

3 years ago

Tonix cuts in­ter­im analy­ses of two tri­als, halves en­roll­ment in one

3 years ago

Up­dat­ed: New da­ta from a mas­sive Parkin­son’s tri­al could lead to break­throughs in drug de­vel­op­ment

3 years ago

Ahead of ad­comm, FDA backs Rex­ul­ti for first ap­proval for ag­i­ta­tion as­so­ci­at­ed with Alzheimer’s de­men­tia

3 years ago
Pharma

As­traZeneca ends dai­ly GLP-1/glucagon tri­als in switch to week­ly in­jec­tion op­tion for NASH, oth­er in­di­ca­tions

3 years ago
Pharma

Take­da tak­ing mag­ni­fy­ing glass to non-vi­ral gene ther­a­py pro­grams as Carmine pact ends

3 years ago
Cell/Gene Tx
First page Previous page 88899091929394 Next page Last page
A service from the Financial Times